Drug Interactions and Monitoring

Introduction to Hydroxyurea and Augmentin

Hydroxyurea acts as an antimetabolite by inhibiting ribonucleotide reductase, preventing the conversion of ribonucleotides to deoxyribonucleotides, thereby interfering with DNA synthesis, and is primarily used in myeloproliferative disorders, sickle cell disease, and psoriasis (off-label) 1
The American Academy of Dermatology notes that hydroxyurea is used in myeloproliferative disorders (polycythemia vera, essential thrombocythemia) 2
Hydroxyurea is used in sickle cell disease, as noted by the National Comprehensive Cancer Network 3 and Pediatrics 4

Hydroxyurea commonly causes bone marrow suppression, and monitoring complete blood counts may be prudent when used concurrently with Augmentin 1
Hydroxyurea may cause temporary impairment of renal tubular function with elevations in serum uric acid, BUN, and creatinine, and Augmentin is primarily excreted through the kidneys, so dose adjustments may be needed in patients with significant renal impairment 1
Both medications can cause gastrointestinal symptoms, including stomatitis, anorexia, nausea, vomiting, diarrhea, and constipation, and exacerbated gastrointestinal symptoms should be watched for 1

In patients with sickle cell disease, penicillin prophylaxis (including amoxicillin) is often prescribed to prevent pneumococcal infections, and no specific contraindications exist for using these medications together 4
Hydroxyurea dosing in children with sickle cell disease should follow established protocols, and Augmentin dosing should be adjusted based on weight and age 4

Monitor complete blood count (CBC) regularly as per standard hydroxyurea monitoring protocols, assess renal function periodically, and watch for exacerbated gastrointestinal symptoms when using these medications concurrently 1
Standard monitoring for the individual side effect profiles of each medication is recommended, with particular attention to complete blood counts, renal function, and gastrointestinal symptoms 1